Indaptus Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Indaptus Therapeutics, Inc. (INDP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $230.89 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-13
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $230.89K, a 273.35% increase from fiscal 2023.
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $61.84K, a 28.88% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $86.95K.
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $16.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $230.89K 10-K · filed 2025-03-13 |
| 2023-12-31 | $61.84K 10-K · filed 2025-03-13 |
| 2022-12-31 | $86.95K 10-K · filed 2024-03-13 |
| 2020-12-31 | $16.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |